Nephrology · Pharmacokinetics
The ongoing trial of S-892216 in patients with renal impairment is significant as it addresses a critical patient population that may have unmet therapeutic needs. Positive outcomes could enhance the drug's market positioning and broaden its therapeutic applications.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/18/2026, 6:03:25 AM
Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The ongoing trial of S-892216 in patients with renal impairment is significant as it addresses a critical patient population that may have unmet therapeutic needs. Positive outcomes could enhance the drug's market positioning and broaden its therapeutic applications. Assessment grounded in 8 ranked evidence items (4 high-relevance).
Portfolio teams should monitor the outcomes to evaluate S-892216's viability in renal impairment, which may open new therapeutic avenues. The strongest clinical anchor is A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls (ClinicalTrials.gov), entity match (shionogi). In Nephrology · Pharmacokinetics, 0 regulatory and 1 competitive items passed relevance filtering for Shionogi.
The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial could provide insights into the drug's safety profile in a critical patient population, potentially influencing its market positioning.
Regulatory risk is concentrated around The results of this trial may influence regulatory decisions regarding labeling and approval for S-892216 in a new patient population, impacting its market entry strategy..
No evidence in this category.
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
ClinicalTrials.govhigh relevance
Entity match (shionogi)
FDA document
View sourceStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing trial of S-892216 in patients with renal impairment is significant as it addresses a critical patient population that may have unmet therapeutic needs. Positive outcomes could enhance the drug's market positioning and broaden its therapeutic applications.
If S-892216 demonstrates a favorable safety profile in renal impairment, it could capture a share of the nephrology market, potentially increasing revenue streams for Shionogi.
The results of this trial may influence regulatory decisions regarding labeling and approval for S-892216 in a new patient population, impacting its market entry strategy.
Key milestones include recruitment progress and initial safety data release from the trial.
Track for follow-up milestones; no immediate action required.